BrainPhys™ Without Phenol Red

Serum-free neurophysiological basal medium for improved neuronal function
BrainPhys™ Without Phenol Red

Serum-free neurophysiological basal medium for improved neuronal function

500 mL
Catalog # 05791
113 USD
Required Products
  1. NeuroCult™ SM1 Neuronal Supplement
    NeuroCult™ SM1 Neuronal Supplement

    Supplement (50X) for the serum-free culture of neurons

Overview

Promote, rather than inhibit, neuronal activity and maturity in your cultured primary or human pluripotent stem cell (hPSC)-derived neurons in a phenol red-free environment.

Based on the formulation by Bardy and Gage (Bardy C et al. PNAS, 2015), BrainPhys™ serum-free neuronal basal medium is optimized to yield a higher proportion of synaptically active neurons by mimicking the central nervous system extracellular environment. Use BrainPhys™ Without Phenol Red to culture primary neurons, differentiate and mature hPSC-derived neurons, record microelectrode array-based neuronal activity, live-fluorescent image neurons, and transdifferentiate somatic cells to neurons without hormonal signaling.

To ensure cell survival in long-term serum-free culture, BrainPhys™ Without Phenol Red must be combined with an appropriate serum-replacement supplement, such as NeuroCult™ SM1 Neuronal Supplement (Catalog #05711) and/or N2 Supplement-A (Catalog #07152).
Advantages
• More representative of the brain’s extracellular environment
• Improved neuronal function and a higher proportion of synaptically active neurons
• Perform functional assays without changing media and shocking cells
• Supports long-term culture of ES/iPS cell- and CNS-derived neurons
• Rigorous raw material screening and quality control ensure minimal lot-to-lot variability
Subtype
Basal Media, Specialized Media
Cell Type
Neural Cells, PSC-Derived, Neurons, Pluripotent Stem Cells
Species
Human, Mouse, Rat
Application
Cell Culture, Differentiation, Maintenance
Brand
BrainPhys
Area of Interest
Disease Modeling, Drug Discovery and Toxicity Testing, Neuroscience, Stem Cell Biology
Formulation
Serum-Free

Scientific Resources

Product Documentation

Document Type Product Name Catalog # Lot # Language
Document Type
Product Information Sheet
Product Name
BrainPhys™ Without Phenol Red
Catalog #
05791
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
BrainPhys™ Without Phenol Red
Catalog #
05791
Lot #
All
Language
English

Educational Materials (11)

Brochure
BrainPhys™ Neuronal Medium for Improved Neuronal Function
Brochure
STEMCELL Neural Product Portfolio
Brochure
hPSC-Derived Neural Cell Research
Brochure
Primary Neuronal Culture: Standardized Media and Reagents
Wallchart
Cell-Reprogramming Technology and Neuroscience
Video
BrainPhys™: A New Way to Culture Neurons
0:55
BrainPhys™: A New Way to Culture Neurons
Webinar
Using hiPSCs to Study Genetic Variants Linked to Schizophrenia
53:22
Using hiPSCs to Study Genetic Variants Linked to Schizophrenia
Webinar
The Road to Functional Human Neuronal Circuits in Vitro
56:27
The Road to Functional Human Neuronal Circuits in Vitro
Webinar
BrainPhys™ Medium Supports the Physiological Activity of Neuronal Tissue in vitro
27:19
BrainPhys™ Medium Supports the Physiological Activity of Neuronal Tissue in vitro
Scientific Poster
BrainPhys™ Neuronal Medium: A Medium Optimized to Support the Synaptic Activity of Neurons Derived from Human Pluripotent Stem Cells and Primary CNS Tissues
Scientific Poster
Determining the Metabolic Requirements of Electrically Active Rodent Primary Neurons in Long-Term Culture

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Publications (2)

American journal of human genetics 2019 Mutations in ACTL6B Cause Neurodevelopmental Deficits and Epilepsy and Lead to Loss of Dendrites in Human Neurons. S. Bell et al.

Abstract

We identified individuals with variations in ACTL6B, a component of the chromatin remodeling machinery including the BAF complex. Ten individuals harbored bi-allelic mutations and presented with global developmental delay, epileptic encephalopathy, and spasticity, and ten individuals with de novo heterozygous mutations displayed intellectual disability, ambulation deficits, severe language impairment, hypotonia, Rett-like stereotypies, and minor facial dysmorphisms (wide mouth, diastema, bulbous nose). Nine of these ten unrelated individuals had the identical de novo c.1027G{\textgreater}A (p.Gly343Arg) mutation. Human-derived neurons were generated that recaptured ACTL6B expression patterns in development from progenitor cell to post-mitotic neuron, validating the use of this model. Engineered knock-out of ACTL6B in wild-type human neurons resulted in profound deficits in dendrite development, a result recapitulated in two individuals with different bi-allelic mutations, and reversed on clonal genetic repair or exogenous expression of ACTL6B. Whole-transcriptome analyses and whole-genomic profiling of the BAF complex in wild-type and bi-allelic mutant ACTL6B neural progenitor cells and neurons revealed increased genomic binding of the BAF complex in ACTL6B mutants, with corresponding transcriptional changes in several genes including TPPP and FSCN1, suggesting that altered regulation of some cytoskeletal genes contribute to altered dendrite development. Assessment of bi-alleic and heterozygous ACTL6B mutations on an ACTL6B knock-out human background demonstrated that bi-allelic mutations mimic engineered deletion deficits while heterozygous mutations do not, suggesting that the former are loss of function and the latter are gain of function. These results reveal a role for ACTL6B in neurodevelopment and implicate another component of chromatin remodeling machinery in brain disease.
Molecular neurodegeneration 2018 iPSC-derived familial Alzheimer's PSEN2 N141I cholinergic neurons exhibit mutation-dependent molecular pathology corrected by insulin signaling. C. L. Moreno et al.

Abstract

BACKGROUND Type 2 diabetes (T2D) is a recognized risk factor for the development of cognitive impairment (CI) and/or dementia, although the exact nature of the molecular pathology of T2D-associated CI remains obscure. One link between T2D and CI might involve decreased insulin signaling in brain and/or neurons in either animal or postmortem human brains as has been reported as a feature of Alzheimer's disease (AD). Here we asked if neuronal insulin resistance is a cell autonomous phenomenon in a familial form of AD. METHODS We have applied a newly developed protocol for deriving human basal forebrain cholinergic neurons (BFCN) from skin fibroblasts via induced pluripotent stem cell (iPSC) technology. We generated wildtype and familial AD mutant PSEN2 N141I (presenilin 2) BFCNs and assessed if insulin signaling, insulin regulation of the major AD proteins Abeta$ and/or tau, and/or calcium fluxes is altered by the PSEN2 N141I mutation. RESULTS We report herein that wildtype, PSEN2 N141I and CRISPR/Cas9-corrected iPSC-derived BFCNs (and their precursors) show indistinguishable insulin signaling profiles as determined by the phosphorylation of canonical insulin signaling pathway molecules. Chronic insulin treatment of BFCNs of all genotypes led to a reduction in the Abeta$42/40 ratio. Unexpectedly, we found a CRISPR/Cas9-correctable effect of PSEN2 N141I on calcium flux, which could be prevented by chronic exposure of BFCNs to insulin. CONCLUSIONS Our studies indicate that the familial AD mutation PSEN2 N141I does not induce neuronal insulin resistance in a cell autonomous fashion. The ability of insulin to correct calcium fluxes and to lower Abeta$42/40 ratio suggests that insulin acts to oppose an AD-pathophysiology. Hence, our results are consistent with a potential physiological role for insulin as a mediator of resilience by counteracting specific metabolic and molecular features of AD.
View All Publications

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.